Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00707993 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 441
- Enrollment target
NCT00707993: Completed Phase 3 study, sponsored by Takeda.
NCT00707993 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 441 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00707993, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 441 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), compared to glipizide in elderly diabetic patients who have not received treatment or are on a single oral medication.
Primary Outcome
The change in the percentage of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 or final visit and glycosylated hemoglobin collected at baseline.
Interventions
- DRUG Glipizide
- DRUG Alogliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 441 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-08 |
| Phase | Phase 3 |
What the finished NCT00707993 record still lists
NCT00707993 is an interventional study that assigns participants to a tested intervention. The registered 441 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 2 interventions - of which Glipizide is the first listed.
NCT00707993 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00707993 about?
NCT00707993 is a clinical study titled "Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics". The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), compared to glipizide in elderly diabetic patients who have not received treatment or are on a single oral medication.
What is the current status of trial NCT00707993?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 441 participants. The study started on 2008-06. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00707993?
The interventions under investigation include: Glipizide (DRUG), Alogliptin (DRUG).
Who is sponsoring clinical trial NCT00707993?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00707993's enrollment target sits among peer trials
441 867th of 2000 higher than 1,134 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02679144 · 441 participants · Phase 2
Neuroblastoma Maintenance Therapy Trial
- NCT03704766 · 442 participants · NA
Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis
- NCT04657068 · 442 participants · Phase 1
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- NCT05410145 · 442 participants · Phase 1
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia